1 min read

ID: 680566

Short Link: https://gregory-ms.com/articles/680566/

Discovery Date: 11 July 2022, 11:20:07 UTC

Published Date: 2022-07-11 10:00:00

Source: PubMed

Link: https://pubmed.ncbi.nlm.nih.gov/35812088/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220711072007&v=2.17.7

Manual Selection: none

Machine Learning Gaussian Naive Bayes Model: true

Abstract

CONCLUSION: This study suggests that nabiximols use is probably safe in stroke patients, therefore cannabinoid usefulness may be further investigated. The lack of nabiximols effect could be related to low pain levels in recruited patients or different spasticity mechanisms between post-stroke and multiple sclerosis patients. Similarly, a beneficial effect of nabiximols could have emerged if more patients with a higher level of spasticity at baseline were recruited.

Noun Phrases in Title

  • Cannabinoid Effect
  • Safety
  • Spasticity
  • Following Stroke
  • A Double-Blind Randomized Placebo-Controlled Study
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.